Ultragenyx Pharmaceutical
Update in progressRARE (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ultragenyx is a biopharmaceutical company focused on rare genetic diseases worldwide. It develops and commercializes biologics and gene therapies, including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii, Dojolvi, and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia. Its late-stage programs include UX143, UX111, DTX401, DTX301, GTX-102, UX701, and UX053. Based in Novato, California, and founded in 2010.
Company score
- Sentiment
- 0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.83
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.38
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.41
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.33
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Emil D. Kakkis M.D., Ph.D.
- Founded2010
- Employees1,371
- Websitewww.ultragenyx.com
Identifiers
- ISINUS90400D1081
- FIGIBBG001RWPDW6
- LEI529900EV44GVDN1DCX77
- CUSIP90400D108
- CIK0001515673